62,406 results on '"NEUTROPENIA"'
Search Results
2. A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC
3. Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia
4. A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
5. Antimicrobial Revision in Persistent Febrile Neutropenia
6. Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
7. Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
8. An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)
9. Next-Generation-Sequencing Approach to Neutropenic Sepsis (NEXUS)
10. A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
11. Baby Detect : Genomic Newborn Screening
12. Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
13. Investigation of the Genetics of Hematologic Diseases
14. Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel (NEUGR-002)
15. Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens (CLEMENT)
16. Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
17. A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma
18. Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial.
19. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
20. Incidence and predictive risk factors of neutropenic sepsis in post-chemotherapy febrile patients in emergency department: A single-center retrospective longitudinal study
21. Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (PRESERVE3)
22. Natural History Study for BEN
23. Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia (PC002)
24. Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
25. Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer
26. Letermovir Use in Heart Transplant Recipients
27. Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim (PELGRAZ)
28. Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (ELSA-FN)
29. Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia (SAFE)
30. Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia (AIHA ITP CIN)
31. A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
32. Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance (DAR-ARC)
33. Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant
34. BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
35. Continuous Versus Bolus Administration of G-CSF in Children With Cancer
36. Early Neutropenic Fever De-escalation of Antibiotics Study (END)
37. Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy (NEUTHREE)
38. Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
39. Probability of Optimal Target Attainment of Amikacin in Patients With Febrile Neutropenia During Treatment for a Hematological Disorder
40. Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia (BIOCAI)
41. A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
42. UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
43. Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
44. Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy (REMEDY)
45. Diagnosing B-cell acute lymphoblastic leukemia in 2 pediatric patients with recent SARS-CoV-2 infection.
46. Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of blaOXA-23 on efficacy.
47. Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations.
48. Seven-day antibiotic therapy for Enterobacterales bacteremia in high-risk neutropenic patients: toward a new paradigm.
49. Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?
50. Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.